Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years.

Failure to achieve CR with induction therapy, and age >65 years are associated with poor outcomes in MS. Allogeneic stem-cell transplant in first remission appears to be the most effective modality for achieving long-term remissions.